Innovation

Our Q1 2024 earnings report

April 25, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Scientist illustration

MSD’s Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023.

“We have begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients,” said Rob Davis, chairman and chief executive officer. “We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.”

MSD anticipates full-year 2024 worldwide sales to be between $63.1 billion and $64.3 billion.

Take a look at the infographic below for more details on Q1 2024 results.

Download infographic

Q1 Financial results infographic
Innovation

Humans, animals and the environment – our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

little girl hugging a white dog

The health of humans, animals and the environment are all interconnected. When the health of one is at risk, the health of all may be at risk.   

We see it in diseases transferred between animals or insects and humans (called zoonotic and vector-borne diseases) such as rabies, Lyme disease, West Nile virus, swine flu and Ebola, among others. We also see it in the growing threat from antimicrobial resistance (AMR), which occurs when bacteria mutate in ways that make the medicines (antimicrobials) used to treat infections ineffective, or when these medicines are used inappropriately to treat viral infections. Or, in diseases in food-producing animals, jeopardizing global food security.

Our increasing vulnerability to such new health challenges has led to a focus on “One Health” — an integrated approach to addressing human, animal and environmental health for the benefit of all.

What is One Health?

One Health is the collaborative approach across multiple disciplines — working locally, regionally, nationally and globally — to prevent, detect and respond to health issues at the interfaces between humans, animals and the environment.

illustration of group of people

It requires collaboration among doctors, veterinarians, nurses, public health practitioners, epidemiologists, agricultural workers, ecologists, wildlife experts, and industry as well as policymakers, communities and even pet owners.

“No one person, organization or sector can address these issues alone. Identifying and responding to growing health challenges requires teamwork,” says Holger Lehmann, DVM, Ph.D., VP, pharmaceuticals research and development, MSD Animal Health.

But what has led to these increasing population health threats?

Why are we more vulnerable to new health challenges?

Society has undergone major changes over the past century. While technology, increased mobility, industrialization, urbanization and globalization have advanced human, animal and environmental health in many ways, they’ve also made us more vulnerable to new health challenges.

For example, according to the Centers for Disease Control and Prevention, every year, millions of people and animals around the world are affected by zoonotic diseases. Scientists estimate that around 60% of emerging infectious diseases that are reported globally come from animals, both wild and domestic. Over 30 new human pathogens have been detected in the last 3 decades, 75% of which have originated in animals.

They can be spread in a number of ways, including direct or indirect contact, vector-borne, foodborne or waterborne. In fact, foodborne pathogens cause millions of cases of sporadic illness and chronic complications, as well as large and challenging outbreaks in many countries and between countries.

In addition, increased exposure to new viruses/bacteria combined with excessive and/or inappropriate use of medicines is causing a rise in AMR. Worldwide, an estimated 4.95 million people died with drug-resistant bacterial infections in 2019, and 1.27 million of these deaths were directly caused by antimicrobial resistance (AMR).

Three main factors are fueling these population health threats, increasing the probability and speed of spreading diseases. They are:

Changes in climate and land use

Deforestation and other disruptions in environmental conditions can provide new opportunities for diseases to develop.

Exponential population growth and expansion into previously uninhabited areas

More people are living in close connection to their companion animals, and in some cases, closer to wild and domestic animals.

Increased international mobility

People, animals and animal products are moving more frequently, easily and widely than ever before.

Our commitment to One Health

With deep expertise in both human and animal health and a commitment to our shared environment, our company is well-positioned to be a leader in the One Health approach.

“We recognize the issues — such as zoonotic and infectious diseases and food safety and security — are interrelated,” says Ian Tarpey, Ph.D., VP, biological research and development, MSD Animal Health. “Our Animal Health and Human Health teams will continue to collaborate to discover and develop preventative solutions for existing and emerging diseases in animals and people.”

Our One Health approach focuses on many areas, including:

Disease prevention

We remain focused on discovering and developing vaccines and technologies to help prevent both human and animal diseases.

Surveillance and monitoring

We’re committed to advocating for and participating in scientifically based surveillance monitoring systems to better understand, track and predict health-related issues.

icon
Respecting our environment

We support science-based, environmentally sound international and national programs to address the challenges to environmental health.

Innovation

Our human and animal health research laboratories collaborate in antimicrobial and vaccine research in many ways including sharing enabling technologies, expertise and evaluation of external opportunities. We’re also investing and developing predictive, monitoring and diagnostic technologies to help animal caretakers make data-driven evaluations of an animal’s health status and optimize their animals’ health and well-being.

Stewardship of essential medicines

We’re playing a leading role in addressing AMR by not only discovering and developing medicines and vaccines to treat and prevent infectious diseases in humans and animals but also supporting responsible use of these products.

Safe and sustainable food supply

We continue to work on developing vaccines and other tools to prevent animal disease to ensure a safe, nutritious, sustainable food supply, and we’ve implemented surveillance initiatives to enable more accurate risk profiling, early disease detection and individualized diagnosis/treatment decisions in livestock.

Corgi and cat running in field

The science of healthier animals

We build strong partnerships in an effort to improve the health of animals around the world, and approach our work with a deep sense of responsibility — to our customers, consumers, animals, society and the planet.

Our work to promote optimal health continues

“One Health recognizes the interconnectedness of human, animal and environmental health, acknowledging that the well-being of each is intricately linked. By embracing a collaborative approach, we can effectively address the complex challenges and promote optimal health for both humans and animals.”

– Dr. Jenelle Krishnamoorthy, VP, global public policy

Innovation

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Photo of river streaming between trees

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Paul Scott, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Andrew (Drew) Otoo, PharmD, president of global vaccines from 2022-2025 and current regional president, MSD. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.

Innovation

How MSD scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

April 4, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

collage of scientists working in labs

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at MSD has been foundational in how we treat metastatic disease, or cancer that has spread.”

  • Dr. Jane Healy
    Vice president and head of oncology early development, MSD Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, our researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through our own research and external collaborations, we’ve developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

  • Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, we’re investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.

    We’re also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  • Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, our scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.

    Similarly, we’re pursuing research that enhances the ability of T cells to recognize and attack tumors.
  • Impacting pathways that can drive cancer growth: We’ve identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, we’re evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

"We're committed to investing in novel research where scientific opportunity and medical need converge."

— Jane Healy

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,250 ongoing clinical trials, which include more than 1,600 trials evaluating combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Healy.

Gloved hands work on labs

Learn more about our oncology pipeline

Innovation

Harnessing innovative technology in drug discovery

MSD scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading edge science to save and improve lives

November 16, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Scientist working in lab

Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow. 

MSD Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.

Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.

“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”

— Adam Weinglass

Executive director in quantitative biosciences
Innovation

Breaking new ground in the UK

We’re accelerating our global efforts and capabilities with our new London Discovery Research Centre and U.K. headquarters

November 10, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

3 people in hard hats breaking ground

Using the power of leading-edge science to help save and improve lives means tapping into scientific talent around the world. That’s why we’re proud to break ground on our new London Discovery Research Centre and U.K. headquarters.

The high-profile site — located opposite King’s Cross Station in the heart of London’s Knowledge Quarter, an impressive cluster of academic, scientific and technological institutions — will be an impactful addition to our growing network of research facilities.

“Our talented discovery scientists in London are an integral part of our global research network.”

  • Dean Li
    President of MSD Research Laboratories

“Patients around the world are waiting for innovations that will help confront the tremendous burden of disease they face, and the kind of world-class scientific exploration this facility will enable is how we accelerate those innovations,” Li added.

Slated to open in 2027, the 270,000-square-foot, 10-story facility will bring together all our U.K. colleagues to help drive medical advances against some of today’s greatest health challenges.  

“With the benefit of London’s thriving life sciences ecosystem and Knowledge Quarter right on our doorstep, I’m excited about the collaboration opportunities, building toward an exciting new chapter, and what this represents for employees and our partnership with the local community and beyond,” said Ben Lucas, managing director, U.K. and Ireland.

Innovation

MSD’s legacy of antimicrobial innovation and action

Delivering on our commitment to fight infectious diseases for more than a century

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Scientist working in lab site

For more than 100 years, MSD has contributed to the discovery and development of novel medicines and vaccines to fight infectious diseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR

The Clinical Use of Sulphapyridine in Pneumococci Pneumonia

1930s

MSD Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.

Penicillin vials on a manufacturing line

1940s

In collaboration with Rutgers University, we developed streptomycin, the first antibiotic effective against tuberculosis. We also helped to develop one of the first methods for mass production of penicillin.

Scientist working in lab site

1950s & 1960s

We developed multiple novel methods to prevent infectious diseases, including pediatric vaccines.

Scientist working in lab site

1970s & 1980s

We received U.S. Food and Drug Administration (FDA) approval for two vaccines, as well as three antibiotics that treat a variety of bacterial infections.

Doctor giving vaccine to child

1990s & 2000s

MSD received U.S. FDA approval for two antifungals, as well as licenses for two vaccines.​

Scientist holding petri dish

2002

With resistance to antibiotics developing faster through people, animals and the environment, we launched one of the world’s largest and longest-running antimicrobial resistance surveillance studies. Called the Study for Monitoring Antimicrobial Resistance Trends (SMART), the program enables researchers to monitor and identify trends in the development of AMR.

Scientist looks into microscope

2010s

We launched an Antimicrobial Stewardship (AMS) Investigator Initiated Studies program, supporting investigator-based, peer-reviewed research supporting the implementation of AMS principles across the globe, with over 20% of studies occurring in low-and middle-income countries.

Building photo

2016

We created the MSD Exploratory Science Center in Cambridge, Massachusetts, focusing on the earliest stages of research into the underlying biology of human disease.

Country flags on site

2016-2017

We supported the first United Nations high-level meeting on AMR and subsequent political declaration in 2016, which set policy action on AMR in motion.

As a next step, we joined the newly founded AMR Industry Alliance – a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help curb antimicrobial resistance.

AMR Action Fund logo

2020

MSD, along with a group of more than 20 leading biopharmaceutical companies, launched the AMR Action Fund to bring 2-4 new antibiotics to patients by the end of the decade.

Institut Pasteur building with Louis Pasteur statue in front

2020s

Our staff have championed government actions to create supportive markets for antimicrobial innovation, including the PASTEUR Act in the U.S., inclusion of transferable exclusivity extensions in the EU pharmaceutical strategy, and other incentives around the world.

By collaborating with policymakers, MSD aims to improve appropriate antibiotic use globally.

Cow drinks milk from bottle

Going forward

In recognition of our leadership in both human and animal health, MSD represents industry in the One Health Global Leaders Group on Antimicrobial Resistance, which advocates for a One Health approach to help ensure antibiotics remain an important tool in improving and maintaining human and animal health.

Innovation

Podcast: Why neuroscience is the ‘final frontier’

Listen as specialists from MSD discuss what they’re most excited about in researching potential treatments for neurologic disorders

July 13, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Members of MSD business development and licensing team

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.

“It’s sort of like the final frontier,” said Joe Herring, scientific AVP, clinical research, in our new podcast. “You’re going off into space to try to figure out how to do very difficult things.”

For more, listen in as Herring sits down with MSD clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today’s breakthroughs and challenges in the field of neuroscience.

Listen to the podcast

Read the full transcript

Explore careers in R&D at MSD

man and woman MSD scientists

Careers

Are you interested in a career in R&D?

Innovation

Individualized neoantigen therapies: exploring one medicine for one patient

Scientists are researching new ways to help train the immune system to fight cancer

April 13, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

MSD's Dr. Jane Healy

Over the past decade, immunotherapy has transformed our understanding of how the immune system can be used to help fight some types of cancer. However, for the last 50 years, scientists have been researching how we could potentially use vaccines to treat cancer — another investigational approach to harness the immune system to help recognize and destroy cancer cells — with little success.

Now we’re looking at a potential therapy that is building upon the learnings of immunotherapy trials from the past and incorporating that into an individualized cancer approach that’s specific to a patient’s own tumor. Researchers are currently exploring the potential of individualized neoantigen therapies to help fight cancer.

Cancer research is becoming more personalized

Cancer is a result of the body’s own cells undergoing mutations which create abnormal proteins in cancer cells, known as neoantigens, that are not usually seen in normal cells. These mutations are unique to each person’s tumor, so that’s one of the reasons why patients who have been diagnosed with the same type of cancer and who have received the same type of treatment may have different responses.

As the treatment of cancer continues to evolve and advance, researchers are focusing on more individualized approaches. This includes a new area of research into individualized neoantigen therapies that use information from a person’s tumor biopsy sample to help develop a therapy unique to their tumor’s mutations.

MSD's Dr. Jane Healy

“This area of research has really captured our imagination of what’s possible in the development of cancer therapeutics.”

  • Dr. Jane Healy
    Vice president and head of oncology early development at MSD Research Laboratories

In collaboration with Moderna, we’re studying this area of research in an effort to advance more individualized approaches to help improve outcomes for people living with cancer.

Learn more about individualized neoantigen therapies

MSD PVC Infographic
Innovation

Proteins in space: taking our research to the final frontier

MSD Research Laboratories scientist Paul Reichert works with the International Space Station to drive innovation

June 29, 2022

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

space shuttle launch

MSD Research Laboratories (MRL) is known for pushing the frontiers of science with its cutting-edge research. And MRL scientist Paul Reichert has taken that concept even further — to space!

Reichert was one of the first scientists in the pharmaceutical industry to propose studying protein crystallization under microgravity conditions, and his work continues today.

“We regularly use crystallization processes for our small molecule and small protein therapeutics. Our goal with these experiments is to identify crystallization processes for biologics for enhanced and simpler drug delivery,” explained Reichert.

Experimental conditions in microgravity are unique because without the force of Earth’s gravity, solutions have reduced convection currents, reduced sedimentation and reduced molecular motion, leading to higher-order crystals with higher purity and more uniform suspensions. Researchers have been able to apply this knowledge ‘on the ground’ by manipulating key variables to mimic those in microgravity, such as using rotational mixers to reduce sedimentation.

Paul and colleagues

Paul Reichert (L) joins April Spinale and Raymond Polniak of the ISS National Laboratory, managed by the Center for the Advancement of Science in Space, Inc. (CASIS), to inspect the experiment

The latest MRL experiment blasted off to the International Space Station in December with astronaut Marc Vande Hei completing the experiment designed to study the effects of purity, mixing, diffusion and temperature on crystallization. Simultaneously, back on Earth, a research team was doing a control experiment in a laboratory for comparison. Reichert is now working alongside other MRL scientists to analyze and compare the results of the experiment run in space against the ground experiment done under the same conditions with gravity.

Paul at the international space station

“I feel so fortunate to have been able to push the frontiers of science with amazing scientists here at MSD and at the ISS National Laboratory. It’s been the highlight of my career.”

  • Paul Reichert
    Associate principal scientist, structural chemistry